Opus Genetics is trading 5.35% down at $3.90 on October 22, 2026, with broad market pressure a plausible backdrop; available reporting does not establish a direct company-specific catalyst. - Reuters reported the Nasdaq fell more than 2% as renewed concerns about AI spending and rising oil prices weighed on markets. - FDA clearance for the OPGx-RDH12 investigational gene therapy was announced October 21, not October 22, and does not explain the decline.